U.S. Household Products Stock News

Syndax Pharmaceuticals secured its third FDA approval within a year, following the launches of Revuforj and Niktimvo. The company is rapidly shifting into a commercial-stage model with revenues now coming from multiple newly approved therapies. Pivotal clinical trials are in progress that could support label expansions and additional indications. Syndax Pharmaceuticals, NasdaqGS:SNDX, is moving from a pure R&D story to an active commercial player, supported by three FDA approved therapies...

Flywire appointed Patrick Blanc as Chief Technology Officer as part of a leadership realignment focused on AI driven product development. Blanc brings payments technology experience from senior roles at Ingenico, Visa, and PayPal. David King moved into the role of Chief Product Officer and Co President of Global Education to support Flywire's product and sector focus. For investors tracking NasdaqGS:FLYW, this leadership reshuffle comes with the stock recently closing at $12.31 and showing...

Republic Airways Holdings (RJET) has drawn fresh attention after recent trading, with the stock up 1.7% on the day and double digit gains over the past month and the past 3 months. See our latest analysis for Republic Airways Holdings. With the latest share price at $21.73, a 1 day share price return of 1.7% builds on a 7 day gain of 10.0% and a 30 day share price return of 26.3%. The year to date move of 10.8% suggests momentum has picked up recently compared with earlier in the year. If...

Chewy appointed Christopher S. Deppe as its new Chief Financial Officer after an extensive search. Deppe previously served as Head of Corporate and Commercial Finance at Chewy and held senior leadership roles at Amazon. This is Chewy’s first major permanent executive appointment following an interim period in the finance role. For investors watching NYSE:CHWY, a permanent CFO is a key piece of the puzzle. Chewy’s shares recently closed at $27.42, with a 3.7% gain over the past week but...

If you are wondering whether Qorvo at around US$82.90 still offers value or is pricing in too much optimism already, you are not alone. The stock has returned 0.8% over the last 7 days and 6.1% over the last 30 days, while the year to date return sits at a 3.9% decline and the 1 year return is 14.0%. This compares to a 19.3% decline over 3 years and a 51.6% decline over 5 years. Recent coverage of Qorvo has focused on its role within the semiconductor sector and how investor expectations are...

Recent Share Performance Snapshot Prestige Consumer Healthcare (PBH) has seen mixed share performance recently, with a 1 day return of roughly a 1.3% decline, a flat result over the past week, and gains over the month and past 3 months. Over longer periods the picture is split, with a 13.2% gain year to date and a 14.9% total return over 3 years, set against an 18.2% total return decline over the past year. See our latest analysis for Prestige Consumer Healthcare. At a share price of $69.30,...

If you are wondering whether Delek US Holdings is still attractively priced after its recent run, this breakdown will help you frame the current share price against what the business might be worth. The stock last closed at US$38.11, with returns of 10.9% over 7 days, 29.1% over 30 days, 28.0% year to date and 146.1% over the past year. These moves naturally raise questions about both upside potential and changing risk. Recent coverage of Delek US Holdings has focused on its position in the...

In February 2026, QCR Holdings, Inc. announced that its Board of Directors approved a cash dividend of US$0.10 per share, payable on April 3, 2026, to shareholders of record as of March 19, 2026, raising the quarterly payout from US$0.06 per share. This sizable step-up in the regular dividend highlights management’s emphasis on returning capital to shareholders while signaling confidence in the company’s financial position. Next, we’ll examine how this materially higher quarterly dividend...

TIC Solutions (TIC) has drawn investor attention after recent trading left the stock around $9.47, with declines over the past week and month, and a roughly flat move over the past 3 months. See our latest analysis for TIC Solutions. Those recent share price declines, including the 3.86% 1 day move and 6.24% 30 day share price return, sit within a weaker picture overall, with a 1 year total shareholder return of 23.38%. If TIC Solutions’ recent pullback has you scanning for other ideas, it...

If you are wondering whether Alkami Technology is starting to look interesting at its current share price, this article will walk through what that price actually implies about the company. The stock last closed at US$16.55, with returns of a 2.8% decline over 7 days, a 21.9% decline over 30 days, a 27.1% decline year to date and a 46.4% decline over the past year, while the 3 year return sits at 7.1%. These moves come as investors continue to track company specific developments and the...

Yum China Holdings (YUMC) is back in focus after reporting Q4 and full year 2025 results that highlighted revenue and margin gains, followed by raised 2026 growth expectations and a sizable insider stock sale. See our latest analysis for Yum China Holdings. At a share price of US$54.91, Yum China’s recent 30 day share price return of 11.11% and year to date gain of 13.99% suggest momentum has picked up, even though the 3 year and 5 year total shareholder returns of 7.32% and 3.21% declines...

Capri Holdings has appointed Tyler Reddien as Chief Financial Officer and Chief Operating Officer, effective March 30, 2026, with interim CFO Rajal Mehta returning to his prior role as Michael Kors brand CFO. The consolidation of finance and operations leadership under Reddien, who brings experience from The Body Shop, Natura &Co, Hertz, and United Airlines, could influence how Capri pursues performance improvement and transformation across its global portfolio. Next, we’ll examine how...

Naturepedic has entered an exclusive retail partnership with GreenRow, a Williams-Sonoma (NYSE:WSM) brand. The collaboration introduces a dedicated assortment of certified organic sleep products for GreenRow customers. The new Aurora Mattress is debuting as part of the deal, expanding Naturepedic's organic mattress lineup. For Williams-Sonoma, known for premium home and kitchen brands, this move adds more certified organic, healthier sleep options to the GreenRow offering. It aligns with...

If you are wondering whether DigitalOcean Holdings is still attractively priced after its recent run, you are not alone. This article will help you weigh what the current share price really reflects. The stock most recently closed at US$56.06, with returns of 1.5% over the last 30 days, 14.5% year to date, and 30.8% over the past year. The last 7 days showed an 11.9% decline that may have changed how some investors see the risk and reward trade off. Recent news coverage has focused on...

Buenaventura (NYSE:BVN) has approved a higher dividend payout policy, supported by strong operating cash flow. The Board also cleared a higher dividend distribution to shareholders under the new framework. The San Gabriel project is approaching completion, with ramp up reported as close to finished. For you as an investor, the combination of a higher dividend payout policy and a near complete San Gabriel ramp up is a key development for Compañía de Minas Buenaventura, a precious metals...

If you are wondering whether OGE Energy is still fairly priced after its recent run, or if the current share price is giving you a margin of safety, this article walks through what the numbers say about value. With the stock at US$49.14 and returns of 3.8% over 7 days, 12.5% over 30 days, 14.6% year to date, 10.3% over 1 year, 56.3% over 3 years and 93.0% over 5 years, many investors are asking whether the current price still makes sense. Recent attention on OGE Energy has focused on how a...

If you are wondering whether LegalZoom.com’s current share price reflects its true worth, you are not alone. This article focuses on what the numbers say about value. The stock last closed at US$7.03, with a 7 day return of 7.2%, but declines of 20.9% over 30 days, 26.7% year to date, and 30.8% over the past year. These moves have put valuation questions front and center for many investors, who are weighing short term swings against the longer term picture. Evergreen coverage like this aims...

PTC Therapeutics (PTCT) shares are in focus after the company released fourth quarter and full year 2025 results, which combined weaker quarterly figures with a sharp full year swing to positive earnings. See our latest analysis for PTC Therapeutics. At a share price of US$68.19, PTC Therapeutics has recently seen weaker short term share price returns, with a 30 day share price return of 9.72% and a year to date share price return of 11.14%. Its 1 year total shareholder return of 23.4% and 3...

Fulton Financial (FULT) is back on investor radars after a recent share pullback, with the stock closing at US$20.45. That is shifting sentiment toward its valuation and the bank’s underlying financial profile. See our latest analysis for Fulton Financial. The recent 5.5% one day share price decline and 8.7% 7 day share price return dip sit against a 90 day share price return of 11.2% and 1 year total shareholder return of 7.3%. This suggests that longer term momentum is still intact despite...

In recent months, BankUnited reported solid quarterly results and continued investments in digital capabilities and new markets, even as its net interest income growth trailed the broader banking industry and analysts projected a weaker efficiency ratio ahead. This tension between operational expansion and concerns about slowing profitability has led some analysts to question how durable BankUnited’s current growth ambitions may be. Next, we’ll examine how these concerns about slowing net...

Amneal Pharmaceuticals (NasdaqGS:AMRX) reported strong Q4 2025 results, highlighting progress across specialty, injectables, biosimilars, and complex generics. The company announced multiple product launches and regulatory approvals, expanding its presence in higher value segments. Management highlighted a promising pipeline, including biosimilars expected to enter the US market. Amneal also emphasized its collaboration with Pfizer on GLP-1 therapies as a key focus area for future...

If you are wondering whether Home Depot at around US$380 is still a solid entry or starting to look expensive, you are not alone. The stock last closed at US$380.72, with returns of 1.6% over 30 days, 10.1% year to date and 69.6% over 5 years, while the 1 year return is a 1.6% decline and the 3 year return is 37.7%. Recent news coverage has focused on Home Depot's role as a bellwether for US housing and renovation trends, and what that might mean for longer term demand. At the same time,...

Caris Life Sciences (NasdaqGS:CAI) reported an interim readout from its Achieve 1 study for the Caris Detect multi cancer early detection blood test. The interim data show sensitivity and specificity that the company says outperform current methylation based approaches. Caris is adding Whole Transcriptome Sequencing to Caris Detect to deepen molecular resolution in the test. The company also introduced a new AI powered breast cancer signature in its Molecular Tumor Board Report to expand...

Oncolytics Biotech (NasdaqCM:ONCY) has completed patient enrollment in its Phase 1/2 GOBLET study. The company is moving ahead with pivotal trials in squamous cell anal cancer and metastatic colorectal cancer. Management is shifting clinical focus and resources toward these rare cancer indications and planning FDA interactions related to potential approval pathways. Oncolytics Biotech focuses on cancer therapies, and the GOBLET study sits at the center of that effort. With enrollment now...